Guiyang Xintian Pharmaceutical Co Ltd
Guiyang Xintian Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of new Chinese patent medicines in China. The company offers products in various dosage forms, including hard capsules, mixtures, granules, gels, tablets, syrups, wine preparation, dews preparations, and two Chinese medicine preparation production lines. Its products are used for the treatment of… Read more
Guiyang Xintian Pharmaceutical Co Ltd (002873) - Total Assets
Latest total assets as of September 2025: CN¥2.09 Billion CNY
Based on the latest financial reports, Guiyang Xintian Pharmaceutical Co Ltd (002873) holds total assets worth CN¥2.09 Billion CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Guiyang Xintian Pharmaceutical Co Ltd - Total Assets Trend (2012–2024)
This chart illustrates how Guiyang Xintian Pharmaceutical Co Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Guiyang Xintian Pharmaceutical Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Guiyang Xintian Pharmaceutical Co Ltd's total assets of CN¥2.09 Billion consist of 31.6% current assets and 68.4% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 6.1% |
| Accounts Receivable | CN¥344.37 Million | 17.7% |
| Inventory | CN¥145.48 Million | 7.5% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥194.01 Million | 10.0% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2012–2024)
This chart illustrates how Guiyang Xintian Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Guiyang Xintian Pharmaceutical Co Ltd's current assets represent 31.6% of total assets in 2024, a decrease from 61.6% in 2012.
- Cash Position: Cash and equivalents constituted 6.1% of total assets in 2024, down from 12.8% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 9.0% of total assets, a decrease from 25.0% in 2012.
- Asset Diversification: The largest asset category is accounts receivable at 17.7% of total assets.
Guiyang Xintian Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Guiyang Xintian Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Guiyang Xintian Pharmaceutical Co Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Guiyang Xintian Pharmaceutical Co Ltd generates 0.44x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Guiyang Xintian Pharmaceutical Co Ltd generates $ 2.68 in net profit.
Guiyang Xintian Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.17 | 1.09 | 1.58 |
| Quick Ratio | 1.57 | 0.84 | 1.41 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥352.07 Million | CN¥ 53.65 Million | CN¥ 299.24 Million |
Guiyang Xintian Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Guiyang Xintian Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.03 |
| Latest Market Cap to Assets Ratio | 0.11 |
| Asset Growth Rate (YoY) | 2.0% |
| Total Assets | CN¥1.95 Billion |
| Market Capitalization | $212.86 Million USD |
Valuation Analysis
Below Book Valuation: The market values Guiyang Xintian Pharmaceutical Co Ltd's assets below their book value (0.11 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Guiyang Xintian Pharmaceutical Co Ltd's assets grew by 2.0% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Guiyang Xintian Pharmaceutical Co Ltd (2012–2024)
The table below shows the annual total assets of Guiyang Xintian Pharmaceutical Co Ltd from 2012 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.95 Billion | +2.02% |
| 2023-12-31 | CN¥1.91 Billion | +3.69% |
| 2022-12-31 | CN¥1.84 Billion | +20.95% |
| 2021-12-31 | CN¥1.52 Billion | -0.75% |
| 2020-12-31 | CN¥1.54 Billion | +41.74% |
| 2019-12-31 | CN¥1.08 Billion | +10.09% |
| 2018-12-31 | CN¥984.31 Million | +14.94% |
| 2017-12-31 | CN¥856.40 Million | +55.84% |
| 2016-12-31 | CN¥549.54 Million | +10.05% |
| 2015-12-31 | CN¥499.36 Million | +6.76% |
| 2014-12-31 | CN¥467.76 Million | +23.18% |
| 2013-12-31 | CN¥379.74 Million | +12.74% |
| 2012-12-31 | CN¥336.84 Million | -- |